Gypenoside IX Suppresses p38 MAPK/Akt/NFκB Signaling Pathway Activation and Inflammatory Responses in Astrocytes Stimulated by Proinflammatory Mediators

摘要: Gypenoside IX (GP IX) is a pure compound isolated from Panax notoginseng. Gypenosides have been implicated to benefit the recovery of enormous neurological disorders. By suppressing activation astrocytes, gypenosides can improve cognitive impairment. However, so far, little known about whether GP could restrain inflammatory responses in astrocytes or reactive astrogliosis. In present study, anti-inflammatory effects were investigated induced by proinflammatory mediators both vitro and vivo. significantly reduced production inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), interleukin-1β (IL-1β) at either protein mRNA level glial cell line C6 cells stimulated lipopolysaccharide (LPS)/TNF-α combination. It also alleviated astrogliosis decreased brain cortex LPS-treated mice. Further study disclosed that inhibited nuclear translocation factor kappa B (NFκB) its transcriptional activity. Meanwhile, attenuated phosphorylation NFκB, inhibitor (IκB), Akt, p38 mitogen-activated kinase (MAPK) under conditions These findings indicated might suppress Akt/p38 MAPK/NFκB signaling pathways. And be promising drug candidate prodrug for therapy neuroinflammatory disorders characterized with